Draft genome assembly files can be found at GenBank accession numbers PHUU00000000.1- PHWY00000000.1 or <https://www.ncbi.nlm.nih.gov/nuccore/PHUV01000001/>. A table indicating which isolates match with specific GenBank accession numbers is available in the Supporting Information files.

Introduction {#sec005}
============

*Staphylococcus aureus* bloodstream infections are an important clinical problem, with associated mortality of 7% to 29% \[[@pone.0195860.ref001]--[@pone.0195860.ref003]\]. Nasal colonization is the antecedent to bloodstream infection in most cases \[[@pone.0195860.ref004]\]. When nasal colonization is identified prior to bloodstream infection, pulsed field gel electrophoresis analyses show that the nasal and bloodstream isolates match in 80% of cases, confirming that the nasal colonizer is the source of the bloodstream infection \[[@pone.0195860.ref005]\]. Despite evidence that *S*. *aureus* colonization increases the risk of infection, the majority of colonized individuals remain free of infection. A clear understanding of the reasons that some colonized individuals develop infection, while others remain healthy, would inform efforts to control this important pathogen.

The events that cause colonization to progress to invasive disease are poorly understood. Clinical risk factors for invasive infections with *S*. *aureus* include end stage renal disease, central venous catheterization, and chronic wounds \[[@pone.0195860.ref006]\]. These risk factors alone do not explain why some colonized people remain free of infection, while others go on to suffer invasive disease. The innate immune system is activated in patients with *S*. *aureus* nasal colonization, but is ineffective in clearing carriage in persistently colonized persons \[[@pone.0195860.ref007]\]. Humoral immunity provides some protection against mortality when patients become bacteremic, but it does not prevent bacteremia \[[@pone.0195860.ref008]\].

Focusing on the pathogen component of the host-pathogen relationship, one may hypothesize that changes in *S*. *aureus* virulence during carriage could lead to invasive infection. Recent studies have used whole genome sequencing to capture the population dynamics and evolution of *S*. *aureus* strains that have colonized the nares and resulted in a single case of bacteremia \[[@pone.0195860.ref009]\] and four cases of recurrent soft tissue infections \[[@pone.0195860.ref010]\]. To further elucidate the evolutionary strategy of *S*. *aureus* strains colonizing the nares, we performed a genomics-based, cohort study of eight patients who were nasal *S*. *aureus* carriers and subsequently developed *S*. *aureus* bacteremia.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

Samples of MRSA nasal colonizing strains obtained and stored for an active methicillin-resistant *S*. *aureus* (MRSA) screening and contact precautions program, as described previously, were used for the study \[[@pone.0195860.ref011]\]. All bloodstream isolates of *S*. *aureus*, including MRSA and methicillin sensitive *S*. *aureus* (MSSA), were obtained through standard clinical laboratory procedures and stored at -80°C. Methicillin-sensitive *S*. *aureus* (MSSA) isolates from nasal swabs were retrieved from storage, and cultured (see below). Clinical data were abstracted from the electronic medical record, and used to calculate the Charlson comorbidity index at the time of the bloodstream infection \[[@pone.0195860.ref012]\].

Ethics declaration {#sec008}
------------------

The study was approved by the Colorado Multiple Institutional Review Board, protocol \#12--0346.

Microbial Culture {#sec009}
-----------------

We identified all patients with *S*. *aureus* bacteremia dated 7/1/2012--6/30/2014, and retrieved blood culture and nasal isolates from stored glycerol stocks. Frozen archived nasal swabs were thawed on ice, suspended in TE buffer (10mM Tris pH 8.0, 1 mM EDTA) by vortexing, and plated on mannitol salt agar and sheep's blood agar plates. Petri plates were evaluated after incubation at 37°C (without CO~2~) for 24 hours. Individual isolates were glycerol stocked and stored at -80°C. For the blood isolates, susceptibility to oxacillin was tested on the Vitek platform, according to manufacturers' instructions. *S*. *aureus* ATCC type strains BAA-1699 (USA100) and BAA-1556 (USA300) were also glycerol stocked and sequenced.

RNAIII qRT-PCR {#sec010}
--------------

Following the method described in Laabei, et al. \[[@pone.0195860.ref013]\] *agr* functionality was tested by qRT-PCR assay of the RNAIII gene and *gyrB* (housekeeping gene). Overnight cultures were diluted 1:100 in TSB media and cells grown for 8 hours. Cell pellets were collected on ice and flash frozen. RNA was extracted using a Qiagen RNeasy Mini kit with on-column DNAse I digestion. cDNA was generated using SuperScript II Reverse Transcriptase (Invitrogen) according to manufacturer's directions using random hexamers (Qiagen). The cDNA was then used for qRT-PCR using DyNAmo ColorFlash SYBR Green qPCR kit (ThermoFisher Scientific) following the manufacturer's recommendations. qRT-PCR was performed on a BIO-RAD CFX96 Touch Real-Time PCR Detection System with the following protocol: 95°C for 7 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. For each reaction, the ratio of RNAIII and *gyrB* transcript number was calculated as follows: 2 ^(Ct\ gyrB-Ct\ RNAIII)^.

DNA extraction and genomic sequencing {#sec011}
-------------------------------------

For genomic DNA sequencing, *S*. *aureus* glycerol stocks were streaked for single colonies on tryptic soy agar plates. Single colonies were grown overnight in 3 mL BHI media. DNA was extracted from cell pellets by mechanical and thermal lysis in a buffer of 10mM Tris, 1mM EDTA, 0.5% NP40 \[[@pone.0195860.ref014], [@pone.0195860.ref015]\]. DNA concentrations were measured using a Qubit 2.0 fluorometer following the manufacturer's protocol for dsDNA HS Assay Kit (Life Technologies) and DNA diluted to 0.2 ng/μL. The NexteraXT DNA sample preparation kit (Illumina, USA) was used to prepare 1 ng of DNA for sequencing on the Illumina MiSeq platform, following the manufacturer's protocol. Paired-end sequencing of multiplexed samples (20--24 samples per sequencer run) was performed using the Illumina MiSeq 600 cycle version 3 reagent kit. For comparison, draft genomes of USA100 (BAA-1699) and USA300 (ATCC-1556) reference strains were also generated in parallel.

Data analysis {#sec012}
-------------

To identify SNPs between pairs of isolates, we used Bowtie2 (v2.2.6) software \[[@pone.0195860.ref016]\] to map paired-end reads to the *S*. *aureus* reference sequence USA300_FPR3757 (ATCC-1556) \[[@pone.0195860.ref017]\]. The USA300_FPR3757 contains three annotated plasmids (pUSA01, pUSA02, and pUSA03). Duplicates were marked and excluded from further analysis using Picard2 RemoveDuplicates tool (<http://broadinstitute.github.io/picard>). SNPs were identified with Freebayes v1.0.2.29 \[[@pone.0195860.ref018]\] using a list (-L) to compare all genomes from a single subject compared to the reference sequence (USA300_FPR3757) and filtered using SnpSift \[[@pone.0195860.ref019]\] for the following qualities (MQM \> 20 and DP \> 40). For each subject, the SnpSift call for Reference (isRef) and Variant (isVar) was completed in a stepwise manner to determine how mutations accumulated over the subject's history. SNPs were annotated from the USA300_FPR3757 genome and classified into functional categories using TIGRFAM \[[@pone.0195860.ref020]\] and Aureowiki \[[@pone.0195860.ref021]\].

The A5 *de novo* assembly pipeline \[[@pone.0195860.ref022]\] was used to construct draft genome assemblies (contigs) from the raw paired-end sequence reads (see GenBank accession numbers PHUU00000000.1- PHWY00000000.1 for published draft genome assemblies). Virulence factors were identified among each set of contigs using the *S*. *aureus* VirulenceFinder version 1.5 database \[[@pone.0195860.ref023]\]. Multi-locus sequencing type (MLST) assignments were made by searching each set of contigs for sequences of the housekeeping genes (*arcC*, *aroE*, *glpF*, *gmk*, *pta*, *tpi*, *yqiL*) and comparing these to a database of *S*. *aureus* types for MLST \[[@pone.0195860.ref024]\]. Mykrobe predictor was used to predict the antibiotic resistant profiles from the A5 pipeline results \[[@pone.0195860.ref025]\].

To infer the evolutionary relationships among the *S*. *aureus* isolates, sequence reads were mapped to a USA300 reference genome (USA300_FPR3757). For each isolate, informative base calls were made only at positions with coverage of \>10 reads and \>90% concordance in base calls across all aligned reads; positions not meeting these criteria were called as "N" and excluded from subsequent analyses. Read-mapping created a genome-wide multiple sequence alignment (\>2.8 million positions) of all included genomic sequences \[[@pone.0195860.ref026]\], from which an approximately-maximum-likelihood phylogenetic tree was generated using FastTree v2.1.10 \[[@pone.0195860.ref027]\] and displayed with Dendroscope v3.5.9 \[[@pone.0195860.ref028]\]. Because no full-length, polished genomic sequences of USA100 were available, we corroborated results by generating trees using as references concatenated contigs USA100 isolate that was sequenced in our laboratory, along with two other full-length reference sequences, NC002953 MSSA (MSSA 476), and NC002951 COL (*Staphylococcus aureus subsp*. *aureus* COL).

Results {#sec013}
=======

Study population {#sec014}
----------------

During the study period there were 64 cases of S. aureus bacteremia identified by prospective weekly review of Clinical Microbiology records. Serial nasal isolates prior to onset of bacteremia were available for eight cases. Those eight subjects were included in this longitudinal study of *S*. *aureus* isolates collected 1--326 days (63 +/- 108 days, mean +/- SD) prior to onset of bacteremia ([Table 1](#pone.0195860.t001){ref-type="table"} and [Fig 1](#pone.0195860.g001){ref-type="fig"}). The case subjects consisted of mostly men (7/8), median age 64 years (range 62--92), and Charlson comorbidity index \[[@pone.0195860.ref012]\] of 3.63 +/- 1.87 (mean +/- SD). Review of cases 4 and 7, which both transiently carried an unusual MRSA strain, identified no transmission opportunities, i.e. there were no shared care providers, or locations of care on wards, clinics or in Imaging. Six of eight bacteremia isolates were MRSA ([Table 2](#pone.0195860.t002){ref-type="table"}). Draft genome sequences were generated for 57 isolates, including three individual replicate isolates for the nasal swabs closest to and farthest in time from the blood isolate (See Tables [1](#pone.0195860.t001){ref-type="table"} and [S1](#pone.0195860.s001){ref-type="supplementary-material"}). A single colony from each blood culture was selected for sequencing due to the previous observation by Laabei et al that there was no genetic diversity when they sequenced 12 isolates sampled at two time points and collected in three bottles from patients with *S*. *aureus* bacteremia \[[@pone.0195860.ref029]\]. For all subjects, the bacteremia isolate is noted as 'B0' whereas the isolates collected from the nares are denoted as N, followed by the number of days prior to bacteremia from which the specimen was collected.

![Time line of nares swabs leading to bacteremia.\
Circles indicate nares swab available, red filled circles indicate a bactermia (blood) isolate sequenced, black filled circles indicate *S*. *aureus* isolate sequenced, unfilled circles indicate no *S*. *aureus* isolate available to be sequenced, grey filled circles indicate that a *S*. *aureus* isolate is available but not sequenced, A represents antibiotic given, and V represents Vancomycin given. (See [Table 1](#pone.0195860.t001){ref-type="table"} for more information).](pone.0195860.g001){#pone.0195860.g001}

10.1371/journal.pone.0195860.t001

###### Patient characteristics and sampling time points.

![](pone.0195860.t001){#pone.0195860.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Time line^a^   Clinical Features^b^                                                                                                                                                                                                                                                                                                              Charlson score
  -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Case 1         62 y/o man with heart failure admitted for diuresis                                                                                                                                                                                                                                                                               2

  T18            Admission to hospital                                                                                                                                                                                                                                                                                                             

  T15            Nares culture positive for MSSA (isolates sequenced-N15a, N15b, N15c).                                                                                                                                                                                                                                                            

  T11            Nares culture positive for MSSA (isolate sequenced- N11).                                                                                                                                                                                                                                                                         

  T0             Nares culture positive for MSSA (isolates sequenced- N0a, N0b, N0c).\                                                                                                                                                                                                                                                             
                 Two of two sets of blood cultures positive for MSSA (isolate sequenced---B0).                                                                                                                                                                                                                                                     

  Case 2         65 y/o man with squamous cell cancer of the base of the tongue and pleura.                                                                                                                                                                                                                                                        6

  T21            Nares screen negative for MRSA                                                                                                                                                                                                                                                                                                    

  T22            Video assisted thoracoscopic surgery and talc pleurodesis.                                                                                                                                                                                                                                                                        

  T20            Nares screen negative for MRSA                                                                                                                                                                                                                                                                                                    

  T13            Nares screen positive for MRSA (isolates sequenced--N13a, N13b, N13c)                                                                                                                                                                                                                                                             

  T1             Purulent drainage chest tube site                                                                                                                                                                                                                                                                                                 

  T0             Nares screen positive for MRSA. One of two sets of blood cultures positive for MRSA (isolate sequenced--B0)                                                                                                                                                                                                                       

  Case 3         62 y/o female with diastolic heart failure, chronic obstructive pulmonary disease, obstructive sleep apnea and obesity hypoventilation syndrome admitted at T-0 with respiratory failure.                                                                                                                                         5

  T108           Admitted with exacerbation of chronic obstructive pulmonary disease. Treated with prednisone, beta agonists and azithromycin (isolates sequenced--N108a, N108b, N108c).                                                                                                                                                           

  T85            Admitted with atrial fibrillation diastolic dysfunction and fluid overload (isolate sequence--N85).                                                                                                                                                                                                                               

  T60            Treated with amoxicillin for sinusitis                                                                                                                                                                                                                                                                                            

  T45            Admitted for exacerbation of heart failure (isolate sequenced--N45).                                                                                                                                                                                                                                                              

  T2             Admitted for exacerbation of heart failure (isolate sequenced--N2a, N2b, N2c).                                                                                                                                                                                                                                                    

  T0             Blood culture positive *S. aureus* (isolate sequenced--B0).                                                                                                                                                                                                                                                                       

  Case 4         92-year-old man with coronary artery disease and end stage renal disease receiving hemodialysis via a tunneled catheter, admitted with sepsis.                                                                                                                                                                                    3

  T326           Admitted with hypotension due to volume shifts during hemodialysis (isolate sequenced--N326).                                                                                                                                                                                                                                     

  T229           Screening nasal swab obtained (isolate sequenced--N229).                                                                                                                                                                                                                                                                          

  T212           Cefazolin x 1 for prophylaxis for hemodialysis catheter placement                                                                                                                                                                                                                                                                 

  T208           Admitted for heart failure and cardiogenic pleural effusion. Screening nasal swab obtained (isolate sequenced--N208).                                                                                                                                                                                                             

  T201           Admitted to outside hospital for MRSA bacteremia. Treated with 6 weeks IV vancomycin.                                                                                                                                                                                                                                             

  T175-T160      Vancomycin after each hemodialysis session.                                                                                                                                                                                                                                                                                       

  T142-T56       Admitted to VA Nursing Home for physical rehabilitation                                                                                                                                                                                                                                                                           

  T56            Discharged after a stay for management of heart failure, screening nasal swab obtained (isolates sequenced--N56a, N56b, N56c).                                                                                                                                                                                                    

  T50            Cefazolin x 1 for prophylaxis with HD catheter placement                                                                                                                                                                                                                                                                          

  T30-T18        Cefazolin after each session of hemodialysis for cellulitis at hemodialysis catheter site.                                                                                                                                                                                                                                        

  T0             Central venous catheter associated bloodstream infection related to hemodialysis catheter (isolates sequenced N0a N0b, N0c, B0).                                                                                                                                                                                                  

  Case 5\        63 y/o man was admitted for upper gastrointestinal hemorrhage due to gastric cancer. Past history of end stage renal disease due to IgA nephropathy, dialyzed via right internal jugular tunneled catheter. Nasal MRSA screening cultures and PCR had been persistently positive \~1.5 years.                                     5

  T12- T8        Peripherally inserted central catheter (PICC) placed for transfusion support. Multiple blood transfusions for GI bleeding.                                                                                                                                                                                                        

  T3             Patient received first of planned 5 fractions of palliative X-ray therapy to control UGI bleeding                                                                                                                                                                                                                                 

  T1             Patient received second dose of XRT.                                                                                                                                                                                                                                                                                              

  T0             He developed fever, with no localizing signs, blood cultures were positive for MRSA (isolates sequenced--N0, B0).                                                                                                                                                                                                                 

  Case 6\        83 y/o man with myelodysplastic syndrome that evolved to acute myelogenous leukemia. He had persistent MRSA nares colonization documented for 17 months prior to first sample on T-122                                                                                                                                            5

  T122\          Brief hospital admission for flank pain that was found to be musculoskeletal in origin.\                                                                                                                                                                                                                                          
                 Nares screen positive for MRSA (isolates sequenced--N122a, N122b, N122c).                                                                                                                                                                                                                                                         

  T25\           Patient presented with fever to 102^0^ F, and no localizing findings. Urinalysis was normal; urine culture grew ampicillin sensitive Enterococcus species. Blood cultures were negative. Antimicrobial therapy was not administered and fevers resolved spontaneously. Nares screen positive for MRSA (isolate sequenced--N25).   

  T22            Patient received his weekly dose of romiplostim (thrombopoietin analog).                                                                                                                                                                                                                                                          

  T14            Patient received his weekly dose of romiplostim (thrombopoietin analog).                                                                                                                                                                                                                                                          

  T7---T0        Fever without localizing signs, attributed to urinary tract infection. Patient treated with ciprofloxacin.                                                                                                                                                                                                                        

  T0             Fever and altered mental status noted. No venous access was in place at the time of presentation. Urine and blood cultures grew MRSA (isolates sequenced--N0a, N0b, N0c, B0).                                                                                                                                                     

  Case 7\        85 y/o man with a history of a left renal laceration from ski accident 12 years previously\                                                                                                                                                                                                                                       0
                 Multiple negative nares screening tests for MRSA over 2 years prior to first positive screening test.                                                                                                                                                                                                                             

  T153           Renal abscess was drained percutaneously and yielded 580 cc pus which grew large number of pansensitive coagulase negative staphylococci, not Staphylococcus lugdunensis. He was treated with vancomycin plus pipracillin-tazobactam for 4 days, then with cotrimoxazole for 30 days.                                             

  T104           Nares screening test positive for MRSA (isolates sequenced--N104a, N104b, N104c).                                                                                                                                                                                                                                                 

  T1             Nares screening test positive for MRSA (isolates sequenced--N1a, N1b, N1c).                                                                                                                                                                                                                                                       

  T0             Renal abscess aspirated, culture grew MRSA. One of two blood cultures grew MRSA (isolate sequenced--B0).                                                                                                                                                                                                                          

  Case 8         62 year old man with peripheral arterial disease and lower extremity ulcers.                                                                                                                                                                                                                                                      3

  T80            Initial visit for evaluation of peripheral arterial disease, and follow-up of revascularizaton surgery at outside hospital. Nares Cepheid PCR screening test positive for MRSA (isolate sequenced, *Staphylococcus haemolyticus*).                                                                                                

  T58            Admitted with gangrene right foot due to peripheral arterial insufficiency. Nares Cepheid PCR screening test positive for MRSA. (no isolate sequenced, 0 colonies on blood agar or mannitol salt)                                                                                                                                 

  T36            Right below knee amputation for uncontrolled infection of foot and peripheral arterial disease.                                                                                                                                                                                                                                   

  T25            Nares screening test positive for MRSA (isolates sequenced--N25a, N25b, N25c).                                                                                                                                                                                                                                                    

  T0             Admitted to hospital with sepsis syndrome. Two of two sets of blood cultures positive for MRSA (isolates sequenced--N0a, N0b, N0c, B0).                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Time zero, T0, is the date of the positive blood culture.

^b^Nasal organisms are identified with the number of days prior to the positive blood culture, e.g. N15 was isolated from a nasal swab obtained 15 days prior to the positive blood culture (B0).

10.1371/journal.pone.0195860.t002

###### Overview of blood isolate strain types inferred *in silico* from genomic sequencing results.

![](pone.0195860.t002){#pone.0195860.t002g}

           MLST   Methicillin Resistance   SCC Mec
  -------- ------ ------------------------ ---------
  Case 1   8      MSSA                     NA
  Case 2   8      MRSA                     IV
  Case 3   5      MSSA                     NA
  Case 4   5      MRSA                     II
  Case 5   5      MRSA                     II
  Case 6   5      MRSA                     II
  Case 7   5      MRSA                     II
  Case 8   5      MRSA                     II

Sequence analyses {#sec015}
-----------------

By mapping reads from each draft genome to a USA300 reference genome sequence (USA300_FPR3757, ATCC-1556), we created a whole-genome multiple-sequence alignment of 2.8 million base pairs. Dendrograms inferred from these alignments (Figs [2](#pone.0195860.g002){ref-type="fig"} and [S1](#pone.0195860.s008){ref-type="supplementary-material"}) show that isolates from two subjects clustered closely with the USA300 reference sequence (\<700 SNPs), while most of the remaining genomes clustered near each other and with the USA100 reference sequence (\<1600 SNPs). In comparison, \>23,000 SNPs were detected through pairwise comparisons of members of the USA300 and USA100 clusters ([Fig 3](#pone.0195860.g003){ref-type="fig"}). For instance, pairwise comparison of USA100 and USA300 type strains comprised 2,655,116 informative positions (i.e., coverage \>10 bases for each sequence, with \>90% of reads concordant for the base call at that position), with base differences identified at 22,339 (0.84%) positions. In general, all isolates obtained from an individual clustered closely to one another; however, some exceptions were noted and will be discussed below (see Case [4](#sec020){ref-type="sec"}, Case [6](#sec022){ref-type="sec"}, and Case [7](#sec023){ref-type="sec"}; [S2 Table](#pone.0195860.s002){ref-type="supplementary-material"}). Through the *in silico* MLST analysis, all of the strains clustering with USA300 and USA100 reference strains were assigned to MLST 8 and MLST 5, respectively. Five additional isolates (from two time points) clustered together and were assigned to MLST 87 (discussed below in Case 4 and Case 7).

![Phylogenetic relationships between *S. aureus* nasal and blood isolates.\
Whole-genome multiple sequence alignments were generated and a maximum-likelihood phylogenetic tree calculated using Fasttree v2.1.10 (40), as described in the text. Multi-locus sequence types were inferred from assembled genomic sequences. A selection of nodes with bootstrap scores \>99% are marked with closed circles (all bootstrap scores are indicated in the cladogram in [S1 Fig](#pone.0195860.s008){ref-type="supplementary-material"}). The scale bar denotes 0.001 base substitutions per position, which is equivalent to \~2800 SNPs over the 2,800,000 genomic positions".](pone.0195860.g002){#pone.0195860.g002}

![Distribution of SNPs.\
A) Distribution of all SNPs identified in *S. aureus* isolates. B) Distribution of Non-Synonymous SNPs identified in *S. aureus* isolates by functional categories defined by Aureowiki.](pone.0195860.g003){#pone.0195860.g003}

Whole-genome multiple sequence alignments were generated and a maximum-likelihood phylogenetic tree calculated using Fasttree, as described in the text. Multi-locus sequence types were inferred from assembled genomic sequences. Multi-locus sequence types were inferred from assembled genomic sequences. A selection of nodes with bootstrap scores \>99% are marked with closed circles (all bootstrap scores are indicated in the cladogram in [S1 Fig](#pone.0195860.s008){ref-type="supplementary-material"}). The scale bar denotes 0.001 base substitutions per position, which is equivalent to \~2800 SNPs over the 2,800,000 genomic positions analyzed.

Next, VirulenceFinder software was used to infer the virulence gene profile of isolates from each subject ([Table 3](#pone.0195860.t003){ref-type="table"}). For simplicity, we restricted this analysis to comparing the earliest nasal isolate with the corresponding B0 isolate from each subject. In all cases, the virulence profile (presence or absence of each gene) of the nasal isolate was identical to that of its paired B0 isolate. The MLST 8 strains encoded a smaller number of virulence genes compared with the MLST 5 strains, while the MLST 87 strains differed notably from both the MLST 5 and MLST 8 strains ([Table 3](#pone.0195860.t003){ref-type="table"}). Antibiotic susceptibility profiles of each B0 isolate and the earliest nasal isolate from each subject were inferred *in silico* and compared using Mykrobe predictor analysis \[[@pone.0195860.ref025]\]. No differences were observed in the predicted antibiotic susceptibility profiles between pairs of isolates from each subject (data not shown). Comparison of the *in silico* antibiotic susceptibility profiles to those determined using the Vitek platform showed concordant results in most cases ([S3 Table](#pone.0195860.s003){ref-type="supplementary-material"}). In the sole exception, Case 7, the prediction of ciprofloxacin sensitivity did not match the Vitek results, which indicated resistance. However, ciprofloxacin has been shown to have a higher false negative prediction rate compared to other antibiotics \[[@pone.0195860.ref025]\].

10.1371/journal.pone.0195860.t003

###### Virulence determinants identified in *S*. *aureus* isolate genomes.

![](pone.0195860.t003){#pone.0195860.t003g}

  ------------------------------------ --- --- --- --- --- --- --- --- ----
  Case number                          1   2   3   4   5   6   7   8   7
  Specimen source                      B   B   B   B   B   B   B   B   N1
  MLST Type                            8   8   5   5   5   5   5   5   87
  *aur* (aureolysin)                   P   P   P   P   P   P   P   P   P
  *hlb* (β-hemolysin)                  P   P   P   P   P   P   P   P   P
  *hlgA* (δ-hemolysin component A)     P   P   P   P   P   P   P   P   P
  *hlgB* (δ-hemolysin component B)     P   P   P   P   P   P   P   P   P
  *hlgC* (δ-hemolysin component C)     P   P   P   P   P   P   P   P   P
  *lukD* (leukocidin E)                P   P   P   P   P   P   P   P   
  *lukE* (leukocidin M)                P   P   P   P   P   P   P   P   
  *sak* (staphylokinase)               P   P   P   P   P   P   P   P   P
  *scn* (Staph complement inhibitor)   P   P   P   P   P   P   P   P   P
  *splA* (serine protease-like A)      P   P   P   P   P   P   P   P   
  *splB* (serine protease-like B)      P   P   P   P   P   P   P   P   
  *seb* (enterotoxin B)                                                P
  *sed* (enterotoxin D)                            P   P   P           
  *seg* (enterotoxin G)                            P   P   P   P   P   
  *sei* (enterotoxin I)                        P   P   P   P   P   P   
  *sej* (enterotoxin J)                        P   P   P   P           
  *sek* (enterotoxin K)                                                P
  *sem* (enterotoxin M)                        P   P   P   P   P   P   
  *sen* (enterotoxin N)                        P   P   P   P   P   P   
  *seo* (enterotoxin O)                        P   P   P   P   P   P   
  *seq* (enterotoxin Q)                                                P
  *ser* (enterotoxin R)                            P   P   P           
  *seu* (enterotoxin U)                            P   P   P   P   P   
  ------------------------------------ --- --- --- --- --- --- --- --- ----

B, blood; N1, nares at time 1; P, present.

SNPs were identified from consensus draft genomes generated through Bowtie2 read-mapping to a USA300 reference genome (USA300_FPR3757) \[[@pone.0195860.ref017]\]. Each genomic sequence was compared within a subject using Freebayes and SnpSift to identify SNPs common within the set of genomic sequences. Forty-two percent of the SNPs resulted in a predicted amino acid change within a protein coding region ([Table 4](#pone.0195860.t004){ref-type="table"} and [Fig 3](#pone.0195860.g003){ref-type="fig"}), 29% were detected in intergenic regions (Tables [5](#pone.0195860.t005){ref-type="table"} and [S4](#pone.0195860.s004){ref-type="supplementary-material"}), and 12% resulted in synonymous mutations within a protein coding region ([S5 Table](#pone.0195860.s005){ref-type="supplementary-material"}). To identify the functions of genes harboring non-synonymous mutations ([Fig 3B](#pone.0195860.g003){ref-type="fig"}), we queried the Aureowiki \[[@pone.0195860.ref021]\] which utilizes the TIGRFAM classification system \[[@pone.0195860.ref020]\]. Hypothetical proteins (18%), and transport and binding proteins (18%), were the two most highly represented functional classes, although a great diversity of functions were observed across the entire set of SNPs ([Table 4](#pone.0195860.t004){ref-type="table"} and [Fig 3B](#pone.0195860.g003){ref-type="fig"}).

10.1371/journal.pone.0195860.t004

###### Accumulation of non-synonymous single nucleotiode polymorphisms.

![](pone.0195860.t004){#pone.0195860.t004g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CASE         USA300POS.   ISREF / ISVAR             GENE               CODON               AA CHANGE                       GENE NAME/FUNCTION                             TIGRFAM CATEGORY                                             ASSOCIATION
  ------------ ------------ ------------------------- ------------------ ------------------- ------------------------------- ---------------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **CASE 1**   2063390      N15 / N11, N0, B0         *sdcS*             `gCc/gAc`           Gly---Asp                       Sodium-dependent dicarboxylate transporter     Transport and binding                                        \-

  **CASE 2**   1537427      N13 / B0                  *ebpS*             `gTc/gCc`           Asp---Ala                       Elastin-binding protein                        Cell wall biogenesis, degradation                            Bacterial adhesion to endothelial cells \[[@pone.0195860.ref030]\]

  **CASE 2**   1138065      N13 / B0                  *polX*             `Ctt/Ttt`           Leu---Phe                       DNA polymerase                                 Cellular process                                             

  **CASE 2**   1951225      N13 / B0                  *epiB*             `aTa/aAa`           Tyr---Leu                       Lantibiotic epidermin biosynthesis protein\    Cellular process                                             Toxin production and resistance, http://aureowiki.med.uni-greifswald.de/SAUSA300_RS09665

  **CASE 2**   2201428      N13 / B0                  *cshA*             `Acc/Gcc`           Gly---Ala                       DEAD/H box family ATP-dependent RNA helicase   DNA metabolism                                               Inactivation results in dysregulation of biofilm formation and hemolysis through modulation of *agr* mRNA stability \[[@pone.0195860.ref031]\]

  **CASE 2**   607085       N13 / B0                  SAUSA300_RS02885   `gGt/gTt`           Gly---Val                       Haloacid dehalogenase-like family (GO)         Energy metabolism                                            Virulence and adhesion \[[@pone.0195860.ref032]\]

  **CASE 2**   1441189      N13 / B0                  *arlS*             `aTg/aAg`           His---Lys                       Two-component sensor histidine kinase          Signal transduction                                          Regulates virulence proteins \[[@pone.0195860.ref033]\]

  **CASE 2**   385424       N13 / B0                  SAUSA300_RS01770   `cCa/cGa`           Trp---Arg                       BglG family transcriptional antiterminator     Transport and binding                                        Up-regulated in *rsp* mutant \[[@pone.0195860.ref034]\]

  **CASE 2**   2486418      N13 / B0                  *lctP*             `aGt/aTt`           Thr---Ile                       L-lactate permease\                            Transport and binding                                        Adaption to fluctuating oxygen environments \[[@pone.0195860.ref035]\]\

  **CASE 2**   1794287      N13 / B0                  SAUSA300_RS08930   `aaG/aaA`           Leu---Lys                       Membrane protein\                              Unknown function                                             

  **CASE 3**   302945       N108, N85, N45, N2 / B0   SAUSA300_RS01340   `Gtt/Ttt`           Val---Phe                       TagB2-CDP-ribitol ribophosphatase              Hypothetical protein                                         Teichoic acid biosynthesis protein

  **CASE 4**   1578750      N56 / N0, B0              SAUSA300_RS07715   `Aaa/Gaa`           Phe---Glu                       phiSLT ORF 78B-like protein                    Regulatory functions                                         Proteasome regulatory subunit C-terminal

  **CASE 6**   357524       N25 / N0, B0              SAUSA300_RS01635   `cCa/cGa`           Pro---Arg                       5\'-nucleotidase\                              Biosynthesis of cofactors, prosthetic groups, carriers       Involved in exoproteome virulence which is modulated by Sae/aureolysin \[[@pone.0195860.ref036]\]

  **CASE 7**   409155       N104 / B0                 *metE*             `gAa/gGa`           Phe---Gly                       Homocysteine methyltransferase                 Amino acid metabolism                                        

  **CASE 7**   1893514      N104 / B0                 *pldB*             `aGc/aTc`           Ala---Ile                       Lysophospholipase                              Biosynthesis of cofactors, prosthetic groups, and carriers   Regulated by SgrS which regulates carbon metabolism and virulence \[[@pone.0195860.ref037]\]

  **CASE 7**   2149003      N104 / B0                 *agrA*             `gAa/gGa`           Glu---Gly                       DNA-binding response regulator                 Central intermediary metabolism                              Regulates expression of several virulence genes \[[@pone.0195860.ref038]\], mutation in this gene during *S*. *aureus* soft skin infection \[[@pone.0195860.ref010]\]

  **CASE 7**   2612136      N104 / B0                 SAUSA300_RS13450   `tCc/tTc`           Gly---Phe                       Lipase_3\                                      Hypothetical protein                                         Lipases enable *S*. *aureus* to invade and destroy host tissues \[[@pone.0195860.ref039]\]

  **CASE 7**   2014786      N104 / B0                 *tagH*             `tGc/tAc`           Ala---Tyr                       Teichoic acid ABC transporter                  Transport and binding                                        Cell wall component involved in virulence \[[@pone.0195860.ref040]\]

  **CASE 8**   2775333      N25 / N0, B0              *clfB*             `ATCCGGG/TTCTGGA`   Asp-Phe, Pro---Trp, Asp---Ile   Clumping factor B                              Cell envelope                                                Promotes bacterial adherence hemodialysis tubing, contributing to the pathogenicity of biomaterial-related infections \[[@pone.0195860.ref041]\]

  **CASE 8**   2775381      N25 / N0, B0              *clfB*             `gTC/aTC`           Asp---Ile                       Clumping factor B                              Cell envelope                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pone.0195860.t005

###### Overview of SNP analysis.
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                                             CASE 1   CASE 2   CASE 3   CASE 4 N56, B0   CASE 4 N326, N208   CASE 5   CASE 6^A^   CASE 7 N104, B0   CASE 8
  ------------------------------------------ -------- -------- -------- ---------------- ------------------- -------- ----------- ----------------- --------
  **TIMEPOINTS**                             4        2        5        3                3                   2        4           3                 3
  **DAY FARTHEST FROM BACTEREMIA**           15       13       112      56               118                 1        122         104               25
  **ISOLATES**                               8        4        9        7                3                   4        7           7                 7
  **SYNONYMOUS**                             2                 1        1                NA                                                         
  **NON-SYNONYMOUS**                         2        10       1                         NA                  5        1           6                 3
  **STOP LOST**                                                                          NA                                                         
  **STOP GAINED**                                                                        NA                                                         
  **NON-CODING**                             3        3        1                         NA                           4           2                 
  **PLASMID SYNONYMOUS**                              4                                  NA                  1                                      
  **PLASMID NON-SYNONYMOUS**                          3                                  NA                  1                                      
  **PLASMID NON-CODING**                              1                                  NA                                                         
  **TOTAL SNPS**                             7        21       3        1                9                   7        5           8                 2
  **MEAN PAIRWISE DISTANCE (SNP)**           7        22       4        0                4                   0        3 (89)      11                1
  **RATE OF DIVERSITFICATION (SNPS/YEAR)**   170      590      10       7                28                  2555     15          28                29

^A^ SNP analysis completed using only N25, N0, B0.

mean pairwise distance SNP shown in () calculated using all four isolates (including N122).

Subject-specific details of the genomic analyses {#sec016}
------------------------------------------------

### Case 1 {#sec017}

Seven SNPs differed among the four time points. All four isolates had one mutation in the membrane protein SAUSA300_RS01130, relative to the USA300 reference sequence, changing the start codon to a tyrosine and presumably resulting in loss of translation of this protein.

### Case 2 {#sec018}

Thirteen SNPs were identified between the N13 and B0 isolates on the genomic backbone and 8 mutations were found on the plasmid pUSA01 (see [S6 Table](#pone.0195860.s006){ref-type="supplementary-material"}). Multiple TIGRFAM protein categories were affected including transport and binding (SAUSA300_RS01770 and lctP) and signal transduction (*arlS*).

### Case 3 {#sec019}

Three SNPs differed among the five isolates. The intergenic SNP was located \~30 bp upstream of the histidine tRNA ligase, which could result in change of transcription of this gene.

### Case 4 {#sec020}

Over the 326-day timespan the subject had an additional MRSA bacteremia episode at 201 days prior to the B0 event. The bloodstream isolate from this infection was not available. The sequencing results for this subject showed that strains N326/N229/N208 were more similar to one another (\~6 SNPs detected) than to the other three isolates (N56/N0/B0), with \~1000 SNPs separating the two sets. Although nasal swabs were collected on days -184 and -142, *S*. *aureus* could not be isolated from either. Two of the three strains sequenced from the N56 time point were MLST 87 and one strain was MLST 5. In contrast, at the N0 time point, all three of the strains sequenced were MLST 5. Only one SNP differed among the N56/N0/B0 strains.

### Case 5 {#sec021}

No mutations were identified between the single nasal and bloodstream isolates (N0 and B0). Although an N13 swab was MRSA positive by Cepheid PCR in the clinical lab, no *S*. *aureus* isolates could subsequently be isolated from the heavy mixed growth from the paired, frozen swab.

### Case 6 {#sec022}

This subject had persistently MRSA-colonized nares documented by the clinical laboratory for 17 months prior to the first sequenced isolate. The N122 isolate's mean pair-wise distance was \~220 SNPs compared to the other three time points (N25, N0, B0), and therefore not included in SNP comparison. The single non-synonymous mutation resulted in an amino acid substitution in a 5'-nucleotidase.

### Case 7 {#sec023}

Three time points were included in the genomic data analysis (N104/N1/B0). Whereas the N104 and B0 samples clustered together ([Fig 2](#pone.0195860.g002){ref-type="fig"}), the three N1 isolates did not cluster with any other isolates from Case 7 and were instead categorized as MLST 87. The Case 4 MLST87 isolates and the Case 7 MLST87 isolates differed by 209--236 SNPs. The N1 isolates were excluded from SNP analysis. The N104 and B0 isolates differed by 8 SNPs, including one in the *agrA* gene, a master-regulator of *S*. *aureus* virulence \[[@pone.0195860.ref042]--[@pone.0195860.ref044]\]. Because RNAIII expression levels are commonly used to assess *agrA* function, we quantified RNAIII and *gyrB* (housekeeping gene) mRNA by qRT-PCR assay \[[@pone.0195860.ref013]\] of *in vitro* cultures of N104, B0, USA100, and USA300. Both the N104 and B0 isolates had relatively low levels of expression compared to either the USA300 or USA100 strains, however, the B0 expression levels were reduced 5-fold compared to N104 (p = 0.04; [Table 6](#pone.0195860.t006){ref-type="table"}).

10.1371/journal.pone.0195860.t006

###### qRT-PCR results for *agr* expression in Case 7.

![](pone.0195860.t006){#pone.0195860.t006g}

               2^(gyrB\ Ct--RNAIII\ Ct)^   Lower bound   Upper bound   p-value relative to Case 7 --N104
  ------------ --------------------------- ------------- ------------- -----------------------------------
  USA300       68.7                        26.0          123.0         0.0002
  USA100       24.7                        5.9           91.5          0.0001
  VA104-N104   0.011                       0.003         0.026         NA
  VA104-B0     0.0018                      0.0007        0.0042        0.038

### Case 8 {#sec024}

Nasal isolates from two time points and one blood isolate were sequenced (N25/N0/B0). Although two earlier nasal swabs were positive for MRSA by Cepheid PCR (N58 and N80), no *S*. *aureus* colonies were recovered from either swab. Three codons, all non-synonymous, differed among the isolates. Two mutations were in the gene *clfB* (clumping factor B, TIGRFAM- cell envelope), which plays a role in nares colonization \[[@pone.0195860.ref045]\]. The third mutation was located in a hypothetical phage membrane protein located near to lukS-PV on the genome (TIGRFAM---DNA metabolism).

Discussion {#sec025}
==========

This study provides longitudinal genomic data comparing nasal colonizing *S*. *aureus* strains collected over 1--326 days prior to the onset of bloodstream infection with the subsequent bloodstream isolates in eight patients. We report several key findings. First, colonization progressed to bloodstream infection without acquisition of new virulence genes in all eight cases. Second, the ratio of non-synonymous to synonymous SNPs was 5.5, consistent with selective pressure on the organisms to evolve in the nasal niche. Third, the most common genes that acquired SNPs were those coding for membrane transport functions, although a larger study is needed to determine whether SNPs are statistically more likely to accumulate in particular categories of genes. Fourth, in one case, mutation in the *agr* gene, with associated abrogation of function, was associated with progression to bacteremia. Finally, when triplicate nasal isolates from a single time point were compared to one another, 2.1 +/- 6.5 SNPs were observed, compared with 26 +/- 66 SNPs observed between time points (within one subject), indicating that most of the observed sequence variation between time points was due to strain evolution, rather than selection of variable strains from within the population.

The results of our genomic analyses show that the *S*. *aureus* strains colonizing the nares were closely related to blood isolates from the same individual, confirming results of previous studies \[[@pone.0195860.ref005], [@pone.0195860.ref009], [@pone.0195860.ref046]\]. Isolates collected from a given subject were more similar to each other (\<26 SNPs across time points within each individual) than to isolates collected from other subjects (\>1000 SNPs between MLST 5 subjects and \>650 SNPs between MLST 8 subjects). Progression from colonization to bacteremia occurred without acquisition of new virulence genes, similar to the study by Calderwood, Desjardins \[[@pone.0195860.ref047]\]. However, in our study nonsynonymous SNPs were identified in two regulators of virulence proteins, *argA* (Case 7) and *arlS* (Case 2), as well as other proteins associated with virulence (*epiB*, *tagH*, and *SAUSA300_RS01635*). For these cases, it is possible that alterations in virulence gene expression resulted in strains with greater propensity to cause bacteremia \[[@pone.0195860.ref033], [@pone.0195860.ref038], [@pone.0195860.ref042]\].

Our work represents the largest longitudinal study of the genomics of *S*. *aureus* colonization prior to invasive infection of humans. Similar to Young, et al., and Azarian, et al. \[[@pone.0195860.ref009], [@pone.0195860.ref010]\] we found a high ratio of non-synonymous to synonymous SNPs, indicating that genomic evolution from carriage to bacteremia involves some selective pressure. We showed evolution of virulence genes, and a mutation on the *agr* regulatory gene, which abrogated its function.

Several studies \[[@pone.0195860.ref048], [@pone.0195860.ref049]\] have suggested the possibility that more than one *S*. *aureus* strain might simultaneously colonize the nasal cavities. Indeed, we found evidence of colonization by multiple strains in Case 4, a persistently MRSA colonized subject who experienced two bacteremia episodes separated by \~200 days. Our results suggest that treatment of the first episode with vancomycin may have temporarily suppressed *S*. *aureus* colonization of the nares. The nasal carriage strain from the first bacteremia episode differed from the carriage/bacteremia isolates from the second bacteremia episode by \~1000 SNPs ([Fig 2](#pone.0195860.g002){ref-type="fig"}). This suggests replacement of the first strain by a different strain, as Azarian observed in two of the four patients in their cohort with MRSA recurrent soft tissue infections \[[@pone.0195860.ref010]\]. At the N56 time point MLST 87 and MLST 5 were present in the nares, but the MLST 5 strain replaced the MLST 87 strain to become the sole nasal strain and bloodstream isolate at Day 0. Similarly, in Case 7 the three isolates sequenced at N104 matched the blood isolate strain (\~10 SNPs different comparing N104 to B0), however, the three nasal isolates at N1 were all identified as MLST 87. In both cases, it is likely that MLST 87 was out-competed by an MLST 5 strain. There was no epidemiologic evidence of transmission of MLST 87 between the two subjects. MLST 87 is an infrequently isolated strain of MRSA \[[@pone.0195860.ref050]\].

In all cases, the profiles of virulence and antibiotic resistance genes inferred by *in silico* analysis remained constant throughout the study and, within an individual, did not differ between bacteremia and nasal-carriage isolates. In agreement with Varshney et al., the virulence gene profiles of the USA300 (MLST 8) strains contained fewer staphylococcal enterotoxin genes than did the USA100 (MLST 5) strains \[[@pone.0195860.ref051]\].

Although the isolates identified from within each subject were relatively similar, SNPs between the nasal isolates and bacteremia isolate were identified in 7 of 8 cases. Similar modes of evolution (SNPs in membrane transport genes) were noted compared to studies that exclusively investigated MLST 8 strains \[[@pone.0195860.ref010]\]. We identified several notable mutations. For example, mutations in *arlS* and *agrA*, which regulate transcription of several virulence factor genes, were identified in Case 2 and Case 7 respectively. One of the intergenic SNPs (Case 6) was located \~20 bp upstream of the alpha-hemolysin transcriptional start site, which could alter transcription and/or translation of the gene. Alterations in alpha-hemolysin expression have been reported to affect virulence in *S*. *aureus* \[[@pone.0195860.ref052]\]. Additionally, several mutations were identified in genes involved in cell adhesion to the nasal epithelium including *ebpS* (Case 2), *SAUSA300_RS02885* (Case 2), *SAUSA3000_RS01340* (Case 3), and *clfB* (Case 8). Disrupted function of these genes could promote bacteremia because reduced adherence to epithelial cells has been linked to greater likelihood of *S*. *aureus* entering the bloodstream \[[@pone.0195860.ref053]\]. Overall, these results reveal the wide genotypic landscape that strains can exploit to evolve diverse virulence mechanisms.

Our study has limitations. Although it is the largest study to date of evolution of *S aureus* in the human host, eight subjects remain a relatively small sample. The cases had a high burden of medical morbidity, and may not reflect the evolution of *S*. *aureus* in otherwise healthy hosts. The time between nasal isolates and bloodstream isolates was variable, depending on clinical events for each case. In Case 7, the bloodstream isolate was compared to a nasal isolate from 104 days earlier. It is unknown at what time the decrease in *agr* function that was observed in the bloodstream isolate occurred.

Use of the USA 300 genome as the reference for USA 100 strains may have limited our ability to identify relevant mutations. However, we found that the USA100 strains aligned well with the USA 300 reference. There are no well characterized, reference strains of USA100 with published sequences for reference. Results of additional analyses comparing the isolates to the USA 100 that was sequenced in our laboratory, and to two full length reference sequences, NC002953 MSSA (MSSA 476), and NC002951 COL (Staphylococcus aureus subsp. aureus COL) were similar to the analysis using the USA300 strain.

The successful recovery of *S*. *aureus* from frozen nasal swabs was somewhat surprising. The stress of freezing may have changed the population of *S*. *aureus* that was recoverable from the swab.

In summary, the results of this study show that 1) genomic mutations accumulate at different rates in human nasal carriage strains of *S*. *aureus*, 2) within each patient, less variability in SNP counts was observed between isolates sampled at a single time-point, compared to between time-points, suggesting that selective pressure within the nasal cavities maintains an evolving, but relatively homogenous *S*. *aureus* population genetic structure, 3) co-colonization by different *S*. *aureus* strains and strain replacement occur occasionally, 4) in a relatively healthy host, deleterious mutation of the *agrA* gene was associated with progression to bacteremia, and 5) progression of *S*. *aureus* colonization to nosocomial infection in patients with extensive co-morbidity is seldom due to acquisition of new virulence determinants, such as antibiotic resistance cassettes or toxin-encoding genes.
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###### Phylogenetic relationships between S. aureus nasal and blood isolates.
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